Cargando…
1339. Effects of Tixagevimab-Cilgavimab in Clinical Practice is Consistent with Preliminary Neutralization Studies
BACKGROUND: Emergency use of tixagevimab-cilgavimab was based on data collected prior to the emergence of SARS-CoV-2 omicron variant and subvariants. Dosing recommendations changed twice based on neutralization data alone, leading to patients receiving different doses at varying intervals. We provid...
Autores principales: | Dluzynski, Daniela, Ssentongo, Paddy, Shaheen, Shareef, Maglakelidze, Natella, Hale, Cory, Henao, Maria Paula, Chinchilli, Vernon M, Paules, Catharine I |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678513/ http://dx.doi.org/10.1093/ofid/ofad500.1176 |
Ejemplares similares
-
Tixagevimab-Cilgavimab Rollout on Common Variable Immunodeficient Patients: Early Lessons from an Academic Allergy and Immunology Clinic
por: Dluzynski, Daniela, et al.
Publicado: (2023) -
Tixagevimab + Cilgavimab: First Approval
por: Keam, Susan J.
Publicado: (2022) -
Tixagevimab and cilgavimab for COVID-19 prophylaxis
Publicado: (2022) -
Tixagevimab/ Cilgavimab Outcomes Among Patients with Immunodeficiency
por: Sullivan, Juliana
Publicado: (2023) -
Optimal Duration of Systemic Corticosteroids in Coronavirus Disease 2019 Treatment: A Systematic Review and Meta-analysis
por: Ssentongo, Paddy, et al.
Publicado: (2023)